Thomas Lars Andresen
Fundador en Nanovi Radiotherapy A/S .
Cargos activos de Thomas Lars Andresen
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Nanovi Radiotherapy A/S
Nanovi Radiotherapy A/S Pharmaceuticals: MajorHealth Technology Nanovi Radiotherapy A/S provides radiotherapy related products for the treatment of cancer. Its product BioXmark is a liquid ready-to-insert fiducial marker, which once inserted into soft tissue forms a semi-solid gel. The firm's platform provides an opportunity to encapsulate chemotherapeutics within the gel. The company was founded by Thomas Lars Andresen and Morten Albrechtsen in 2012 and is headquartered in Kongens Lyngby, Denmark. | Director/Miembro de la Junta | 01/01/2012 | - |
Fundador | 01/01/2012 | - | |
T-Cypher Bio Ltd.
T-Cypher Bio Ltd. Miscellaneous Commercial ServicesCommercial Services T-Cypher Bio Ltd. is a British biotechnology company. The company was founded in 2015. Thomas Lars Andresen has been the CEO of the company since 2021. | Director/Miembro de la Junta | 01/08/2021 | - |
Director Ejecutivo | 01/08/2021 | - |
Historial de carrera de Thomas Lars Andresen
Antiguos cargos conocidos de Thomas Lars Andresen.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | Fundador | - | - |
Corporate Officer/Principal | - | - | |
MonTa Biosciences ApS
MonTa Biosciences ApS BiotechnologyHealth Technology MonTa Biosciences ApS engages in research and development in biotechnology for cancer immunotherapy. Its technology offers a solution to deliver immune stimulating compounds directly to immune cells in the blood. The company was founded by Thomas Lars Andresen, Jonas Henriksen, and Simon Skjøde Jensen in August 2014 and is headquartered in Brønshøj, Denmark. | Fundador | 01/08/2014 | - |
LiPlasome Pharma A/S
LiPlasome Pharma A/S Pharmaceuticals: MajorHealth Technology LiPlasome Pharma A/S develops, produces and supplies drugs for chemotherapy treatment. It has developed a technology based on incapsulation of chemotherapy in liposomes (fatty molecules) that will only dissolve in and around cancer tissue (tumors or metastases). The firm’s technology will improve chemotherapy treatment within a wide range of cancer diseases significantly as it improves the balance between effect and side effects. LiPlasome’s first drug candicate LiplaCis which is a liposonal formulation of Cisplatin, is in clinical phase 1. The company was founded in January 2001 by Ole Gunner Mouritsen and is headquartered in Hoersholm, Denmark. | Director Técnico/Científico/I+D | - | - |
Formación de Thomas Lars Andresen.
Technical University of Denmark | Doctorate Degree |
Estadísticas
Internacional
Dinamarca | 5 |
Estados Unidos | 2 |
Reino Unido | 2 |
Operativa
Founder | 3 |
Director/Board Member | 2 |
Doctorate Degree | 1 |
Sectorial
Health Technology | 5 |
Consumer Services | 2 |
Commercial Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 5 |
---|---|
Nanovi Radiotherapy A/S
Nanovi Radiotherapy A/S Pharmaceuticals: MajorHealth Technology Nanovi Radiotherapy A/S provides radiotherapy related products for the treatment of cancer. Its product BioXmark is a liquid ready-to-insert fiducial marker, which once inserted into soft tissue forms a semi-solid gel. The firm's platform provides an opportunity to encapsulate chemotherapeutics within the gel. The company was founded by Thomas Lars Andresen and Morten Albrechtsen in 2012 and is headquartered in Kongens Lyngby, Denmark. | Health Technology |
LiPlasome Pharma A/S
LiPlasome Pharma A/S Pharmaceuticals: MajorHealth Technology LiPlasome Pharma A/S develops, produces and supplies drugs for chemotherapy treatment. It has developed a technology based on incapsulation of chemotherapy in liposomes (fatty molecules) that will only dissolve in and around cancer tissue (tumors or metastases). The firm’s technology will improve chemotherapy treatment within a wide range of cancer diseases significantly as it improves the balance between effect and side effects. LiPlasome’s first drug candicate LiplaCis which is a liposonal formulation of Cisplatin, is in clinical phase 1. The company was founded in January 2001 by Ole Gunner Mouritsen and is headquartered in Hoersholm, Denmark. | Health Technology |
Torque Therapeutics, Inc.
Torque Therapeutics, Inc. BiotechnologyHealth Technology Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA. | Health Technology |
MonTa Biosciences ApS
MonTa Biosciences ApS BiotechnologyHealth Technology MonTa Biosciences ApS engages in research and development in biotechnology for cancer immunotherapy. Its technology offers a solution to deliver immune stimulating compounds directly to immune cells in the blood. The company was founded by Thomas Lars Andresen, Jonas Henriksen, and Simon Skjøde Jensen in August 2014 and is headquartered in Brønshøj, Denmark. | Health Technology |
T-Cypher Bio Ltd.
T-Cypher Bio Ltd. Miscellaneous Commercial ServicesCommercial Services T-Cypher Bio Ltd. is a British biotechnology company. The company was founded in 2015. Thomas Lars Andresen has been the CEO of the company since 2021. | Commercial Services |
- Bolsa de valores
- Insiders
- Thomas Lars Andresen
- Experiencia